Rivaroxaban Outmatched by VKAs for AF in Rheumatic Heart Disease

A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS trial at ESC 2022.
Medscape Medical News

source https://www.medscape.com/viewarticle/979861?src=rss

Comments

Popular posts from this blog

New AAFP practice guideline sets blood pressure targets for adults with hypertension

RA and RA-ILD Linked to Higher Lung Cancer Risk

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?